|
1
|
Centro Nacional para la Salud de la
Infancia y la Adolescencia. (CENSIA): Comportamiento epidemiológico
del cáncer en menores de 18 años. México 2008-2014. Secretaria de
Salud, 2014. http://censia.salud.gob.mx/contenidos/descargas/cancer/20160601_Boletin2014_SEDP12sep16_4.pdf.
|
|
2
|
Smith MA, Seibel NL, Altekruse SF, Ries
LA, Melbert DL, O'Leary M, Smith FO and Reamen GH: Outcomes for
children and adolescents with cancer: Challenges for the
twenty-first century. Int J Clin Oncol. 28:2625–2634.
2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Rendón-Macías ME, Reyes-Zepeda NC,
Villasís-Keever MÁ, Meneses SJ and Núñez AE: Tendencia mundial de
la supervivencia en pacientes pediátricos con leucemia
linfoblástica aguda. Revisión de las últimas cuatro décadas. Bol
Med Hosp Infant Mex. 69:153–163. 2012.
|
|
4
|
Layton-Tovar C: Factores de pronóstico en
leucemia linfoblástica aguda pediátrica: Posibles marcadores
moleculares. Rev Med Investig. 3:85–91. 2015.
|
|
5
|
Terwilliger T and Abdul-Hay M: Acute
lymphoblastic leukemia: A comprehensive review and update. Blood
Cancer J. 7(e577)2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Johansen JS, Hoyer PE, Larsen LA, Price PA
and Møllgård K: YKL-40 protein expression in the early developing
human musculoskeletal system. J Histochem Cytochem. 55:1213–1228.
2007.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Johansen JS, Jensen BV, Roslind A, Nielsen
D and Price P: Serum YKL-40, a new prognostic biomarker in cancer
patients? Cancer Epidemiol Biomarkers Prev. 15:194–202.
2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Prakash M, Bodas M, Prakash D, Nawani N,
Khetmalas M, Mandal A and Eriksson C: Diverse pathological
implications of YKL-40: Answers may lie in ‘outside-in’ signaling.
Cell Signal. 25:1567–1573. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chen HT, Zheng JM, Zhang YZ, Yang M, Wang
YL, Man XH, Chen Y, Cai QC and Li ZS: Overexpression of YKL-40
predicts poor prognosis in patients undergoing curative resection
of pancreatic cancer. J Pancreas. 46:323–334. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kang EJ, Jung H, Woo OH, Park KH, Woo SU,
Yang DS, Kim AR, Lee JB, Kim YH, Kim JS and Seo JH: YKL-40
expression could be a poor prognostic marker in the breast cancer
tissue. Tumor Biol. 35:277–286. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Steponaitis G, Skiriutė D, Kazlauskas A,
Golubickaitė I, Stakaitis R, Tamašauskas A and Vaitkienė P: High
CHI3L1 expression is associated with glioma patient survival. Diagn
Pathol. 11(42)2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Erturk K, Tas F, Serilmez M, Bilgin E and
Yasasever V: Clinical significance of serum Ykl-40
(chitinase-3-like-1 protein) as a biomarker in melanoma: An
analysis of 112 Turkish patients. Asian Pac J Cancer Prev.
18:1383–1387. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Schultz NA and Johansen JS: YKL-40-A
protein in the field of translational medicine: A role as a
biomarker in cancer patients? Cancers (Basel). 2:1453–1491.
2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Volck B, Johansen JS, Stoltenberg M,
Garbarsch C, Price PA, Ostergaard M, Ostergaard K, Løvgreen-Nielsen
P, Sonne-Holm S and Lorenzen I: Studies on YKL-40 in knee joints of
patients with rheumatoid arthritis and osteoarthritis. Involvement
of YKL-40 in the joint pathology. Osteoarthritis Cartilage.
9:203–214. 2001.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chupp GL, Lee CG, Jarjour N, Shim YM, Holm
CT, He S, Dziura JD, Reed J, Coyle AJ, Kiener P, et al: A
chitinase-like protein in the lung and circulation of patients with
severe asthma. N Engl J Med. 357:2016–2027. 2007.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Letuve S, Kozhich A, Arouche N,
Grandsaigne M, Reed J, Dombret MC, Kiener PA, Aubier M, Coyle AJ
and Pretolani M: YKL-40 is elevated in patients with chronic
obstructive pulmonary disease and activates alveolar macrophages. J
Immunol. 181:5167–5173. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Boot RG, Van Achterberg TA, Van Aken BE,
Renkema GH, Jacobs MJ, Aerts JM and de Vries CJ: Strong induction
of members of the chitinase family of proteins in atherosclerosis.
Chitotriosidase and human cartilage gp-39 expressed in lesion
macrophages. Arterioscler Thromb Vasc Biol. 19:687–694.
1999.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Rathcke CN, Johansen JS and Vestergaard H:
YKL-40, a biomarker of inflammation, is elevated in patients with
type 2 diabetes and is related to insulin resistance. Inflamm Re.
55:53–59. 2006.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bergmann OJ, Johansen JS, Klausen TW,
Mylin AK, Kristensen JS, Kjeldsen E and Johnsen HE: High serum
concentration of YKL-40 is associated with short survival in
patients with acute myeloid leukemia. Clin Can Res. 11:8644–8652.
2005.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hurmale AK, Choudhary SK, Bhaskar SK,
Jatawa SK, Yadav M and Tiwari A: Overexpression of chitinase like
protein YKL-40 in leukemia patients. J BioSci Biotech. 2:215–220.
2013.
|
|
21
|
Organista-Nava J, Gómez-Gómez Y,
Illades-Aguiar B, Del Carmen Alarcón-Romero L, Saavedra-Herrera MV,
Rivera-Ramírez AB, Garzón-Barrientos VH and Leyva-Vázquez MA: High
miR-24 expression is associated with risk of relapse and poor
survival in acute leukemia. Oncol Rep. 33:1639–1649.
2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
US Food, Drug Administration: Clinical
trial endpoints for the approval of cancer drugs and biologics:
Guidance for industry. https://www.fda.gov/media/71195/download. Published
December 2018. Accessed August 14, 2019.
|
|
23
|
Wang D, Zhai B, Hu F, Liu C, Zhao J and Xu
J: High YKL-40 serum concentration is correlated with prognosis of
Chinese patients with breast cancer. PLoS One.
7(e51127)2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Thongsom S, Chaocharoen W, Silsirivanit A,
Wongkham S, Sripa B, Choe H, Suginta W and Talabnin C:
YKL-40/chitinase-3-like protein 1 is associated with poor prognosis
and promotes cell growth and migration of cholangiocarcinoma. Tumor
Biol. 37:9451–9463. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Xu CH, Yu LK and Hao KK: Serum YKL-40
level is associated with the chemotherapy response and prognosis of
patients with small cell lung cancer. PLoS One.
9(e96384)2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kotowicz B, Fuksiewicz M, Jonska-Gmyrek J,
Wagrodzki M and Kowalska M: Preoperative serum levels of YKL 40 and
CA125 as a prognostic indicators in patients with endometrial
cancer. Eur J Obstet Gynecol Reprod Biol. 215:141–147.
2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhang JP, Yuan HX, Kong WT, Liu Y, Lin ZM,
Wangs WP and Guo JM: Increased expression of Chitinase 3-like 1 and
microvessel density predicts metastasis and poor prognosis in clear
cell renal cell carcinoma. Tumour Biol. 35:12131–12137.
2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ringsholt M, Hogdall EV, Johansen JS,
Price PA and Christensen LH: YKL-40 protein expression in normal
adult human tissues-an immunohistochemical study. J Mol Histol.
38:33–43. 2007.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Borowitz MJ, Devidas M, Hunger SP, Bowman
WP, Carroll AJ, Carroll WL, Linda S, Martin PL, Pullen DJ,
Viswanatha D, et al: Clinical significance of minimal residual
disease in childhood acute lymphoblastic leukemia and its
relationship to other prognostic factors: A children's oncology
groups study. Blood. 111:5477–5485. 2008.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lenk L, Alsadeq A and Schewe DM:
Involvement of the central nervous system in acute lymphoblastic
leukemia: Opinions on molecular mechanisms and clinical
implications based on recent data. Cancer Metastasis Rev.
39:173–187. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Shao R, Hamel K, Petersen L, Cao QJ,
Arenas RB, Bigelow C, Bentley B and Yan W: YKL-40, a secreted
glycoprotein, promotes tumor angiogenesis. Oncogene. 28:4456–4468.
2009.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Recklies AD, White C and Ling H: The
chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39)
stimulates proliferation of human connective-tissue cells and
activates both extracellular signal regulated kinase- and protein
kinase B-mediated signalling pathways. Biochem J. 365:119–126.
2002.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Johansen JS, Drivsholm L, Price PA and
Christensen IJ: High serum YKL-40 level in patients with small cell
lung cancer is related to early death. Lung Cancer. 46:333–340.
2004.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Sanchez VE, Nichols C, Kim HN, Gang EJ and
Kim YM: Targeting PI3K signaling in acute lymphoblastic leukemia.
Int J Mol Sci. 20(412)2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hoellenriegel J, Meadows SA, Sivina M,
Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A,
Miller LL, et al: The phosphoinositide 3'-kinase delta inhibitor,
CAL-101, inhibits B-cell receptor signaling and chemokine networks
in chronic lymphocytic leukemia. Blood. 118:3603–3612.
2011.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Billottet C, Grandage VL, Gale RE,
Quattropani A, Rommel C, Vanhaesebroeck B and Khwaja A: A selective
inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell
proliferation and survival and increases the cytotoxic effects of
VP16. Oncogene. 25:6648–6659. 2006.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Bojesen SE, Johansen JS and Nordestgaard
BG: Plasma YKL-40 levels in healthy subjects from the general
population. Clin Chim Acta. 412:709–712. 2011.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Johansen JS: Studies on serum YKL-40 as a
biomarker in diseases with inflammation, tissue remodelling,
fibroses and cancer. Dan Med Bull. 53:172–209. 2006.PubMed/NCBI
|
|
39
|
Recklies AD, Ling H, White C and Bernier
SM: Inflammatory cytokines induce production of CHI3L1 by articular
chondrocytes. J Biol Chem. 280:41213–41221. 2005.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Johansen JS, Lottenburger T, Nielsen HJ,
Jensen JE, Svendsen MN, Kollerup G and Christensen IJ: Diurnal,
weekly, and long-time variation in serum concentrations of YKL-40
in healthy subjects. Cancer Epidemiol Biomarkers Prev.
17:2603–2608. 2008.PubMed/NCBI View Article : Google Scholar
|
